Document:

Unassociated Document

EXHIBIT 4.9

June __, 2004

 

BioLineRx Ltd.

Hartum Street

P.O. Box 45158

Jerusalem, 91450

Israel

Attn:  CEO

Dear Sirs,

	
  

	
Re:

	
First Amendment of Research and License Agreement, Dated April 15, 2004, by and Among BioLineRX Ltd., Ramot at Tel Aviv University, Ltd and Bar-Ilan Research and Development Company Ltd. the "Agreement")

 

You have brought to our attention the fact that Section 9.1.1 of the Agreement (Licensor Confidential Information) has created a problem with respect to your ability to enter into agreements with potential contractors/collaborators and to attract investors.  Specifically, the provision states that your obligations of confidentiality and non-use (other than for the purposes of the Agreement) remain in effect during the term of the agreement, and for five (5) years thereafter.  As you have explained to us, potential contractors/collaborators are unwilling to be bound by such confidentiality and non-use obligations with respect to the Confidential Information (as defined in the Agreement) for such undefined term.  Therefore, in order to enable you to continue to develop Licensed Product (as defined in the Agreement) and to exercise your rights and fulfill your obligations under the Agreement, we hereby agree to amend the agreement as follows, effective immediately:

The following shall be inserted at the end of Section 9.1.1:

"Notwithstanding anything to the contrary in this Section 9.1.1, Bioline may disclose Licensor Confidential Information to actual and potential business partners, collaborators, investors, contractors, service providers and consultants, provided, in each case, that such recipient of Confidential Information first enters into a legally binding agreement with BioLine which imposes confidentiality and non-use obligations with respect to Confidential Information comparable to those set forth in this Agreement for a period of least five (5) from the date of disclosure of Licensor Confidential Information to such recipient."

All other provisions of the Agreement shall remain unchanged.

Please indicate your agreement to the above amendment to the Agreement by signing below.

	  	  	
Sincerely,

	  	  	  
	
Ramot at Tel Aviv University Ltd.

	  	
Bar-Ilan Research and Development

	  	  	
Company Ltd.

	  	  	  
	
By:

	

/s/ ISAAC KOHLBERG

	  	
By:

	

/s/ GABRIEL KENAN

	  	  	  	  	  
	
Name: 

	

ISAAC KOHLBERG

	  	
Name: 

	

GABRIEL KENAN

	  	  	  	  	  
	
Title:

	

CEO

	  	
Title:

	

CEO

Agreed to and Accepted:

BioLineRx Ltd.

	
By: 

	
/s/ Yuri Shoshan   /s/ Morris Laster

	  
	  	  	  
	
Name: 

	
Yuri Shoshan           Morris Laster

	  
	  	  	  
	
Title:

	
VP Finance           CEOUnassociated Document

EXHIBIT 4.10

AMENDMENT AGREEMENT

THIS AMENDMENT AGREEMENT, dated as of the 20th day of December, 2005, (the “Effective Date”), is entered into by and between BioLineRx Ltd. (“BioLine”), Bar-Ilan Research and Development Company Ltd. (“BIRAD”) and Ramot at Tel Aviv University Ltd. (“Ramot”, and together with BIRAD, the “Licensors”).

WHEREAS, BioLine and the Licensors entered into that certain Research and License Agreement dated as of April 15, 2004 (the “Research and License Agreement”); and

WHEREAS, the parties desire to amend the Research and License Agreement as set out herein;

NOW, THEREFORE, the parties agree as follows:

1.            Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Research and License Agreement.

2.            Section 13.4.3 of the Resarch and License Agreement shall be deleted in its entirety and replaced with the following:

“13.4.3. Transfer of Regulatory Filings and Know How.  In the event BioLine terminates this Agreement pursuant to Section 13.3.1 or Ramot terminates this Agreement pursuant to Section 6.4, 13.3.2 or 13.3.3 (except in the circumstances set out in Section 13.3.3.2), BioLine shall promptly deliver and assign to Licensors (a) all documents and other materials filed by or on behalf of BioLine and its Affiliates with Regulatory Agencies in furtherance of applications for Regulatory Approval in the relevant country with respect to Licensed Products; and (b) all intellectual property, inventions, conceptions, compositions, materials, methods, processes, data, information, records, results, studies and analyses, discovered or acquired by, or on behalf of BioLine and its Affiliates which relate directly to actual or potential Licensed Products; provided, however, that to the extent that any of the items set forth in clauses (a) or (b) were developed using funds granted by the Office of Chief Scientist of the Israel Ministry of Industry, Trade and Labor (the “OCS”), such items are and remain subject to the rules and regulations of the OCS, including without limitation, the Law for the Encouragement of Industrial Research & Development, 1984.  The Licensors, the TAU Team and the BIU Team shall be entitled to freely use and to grant others the right to use all such materials, documents and know-how delivered pursuant to this 13.4.3.”

3.            Except as amended pursuant to this Amendment Agreement, the terms of the Research and License Agreement shall remain in full force and effect.

[Remainder of page intentionally left blank.  Signature page follows.]

  

  

  

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the date first written above.

	
Ramot at Tel Aviv University Ltd.

	  	
BioLineRx Ltd.

	 	 	 
	
By: /s/ Ze’ev Weinfeld, Ph.D.

	  	
By: /s/ Yuri Shoshan

	 	 	 
	
Name: Ze’ev Weinfeld, Ph.D.

	  	
Name: Yuri Shoshan

	 	 	 
	
Title: Executive Vice President

	  	
Title: Vice President

	
          Business Development

	  	
Finance and Corporate Development

	  	  	  
	
Bar-Ilan Research and Development Company Ltd.

	  	  
	  	  	  
	
By: /s/ Gabriel Kenan

	  	  
	 	 	 
	
Name:Gabriel Kenan

	  	  
	 	 	 
	
Title: CEOUnassociated Document

EXHIBIT 4.11

AMENDMENT AGREEMENT

THIS AMENDMENT AGREEMENT, dated as of the 7th day of March, 2006, (the "Effective Date"), is entered into by and between BioLineRx Ltd. ("BioLine"), Bar-Ilan Research and Development Company Ltd. ("BIRAD") and Ramot at Tel Aviv University Ltd. ("Ramot", and together with BIRAD, the "Licensors").

WHEREAS, BioLine and the Licensors entered into that certain Research and License Agreement dated as of April 15, 2004 (the "Research and License Agreement"); and

WHEREAS, BioLine and the Licensors entered into an amendment agreement dated June 2004 (the "First Amendment Agreement") to amend the Research and License Agreement; and

WHEREAS, BioLine and the Licensors desire to further amend the Research and License Agreement as set out herein;

NOW, THEREFORE, the parties agree as follows:

1. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Research and License Agreement.

2. Section 1.21 of the Resarch and License Agreement shall be deleted in its entirety and replaced with the following:

"1.21 "Licensed Product" shall mean any of the following:

(i) any therapeutic product that comprises, contains or incorporates Licensor Technology; or

(ii) Any therapeutic product that comprises, contains, or incorporates any compound that is covered by a Valid Patent Claim under the Joint Patent Rights.

3. The following new Section 1 .41 shall be added following Section 1.40:

"1.41 "Valid Patent Claim " shall mean a claim of a Licensed Patent Right for as long as such claim shall not have expired or been held invalid in a final non appealable court judgment or patent office decision in the relevant jurisdiction, or an appeal for it has not been filed within the time allowed for an appeal.

  

  

  

4. The following shall be added at the end of the last sentence of section 5.1:

"..., and subject further, to the rights of employees, students and other researchers of TAU and BIU to practice and utilize such rights and licenses solely for academic research purposes within TAU and BIU (the "Academic Research"). Notwithstanding the foregoing, any in vivo experimentation that may be included within the scope of Academic Research that is conducted by, or on behalf of Ramot or BIRAD, shall require the prior written approval of BioLine if and to the extent that such research involves in vivo experimentation of compounds that are currently being developed as Licensed Products by BioLine, such approval not to be unreasonably delayed or withheld. For the removal of doubt, Ramot, Tel Aviv University, BIRAD and BIU shall not obtain funding for Academic Research from any party on terms that (i) give such party any rights to the Licensed Technology that are inconsistent with the rights granted to BioLine hereunder, or (ii) limit in any manner the scope or terms of the license and rights granted to BioLine hereunder.

5. Except as amended pursuant to this Amendment Agreement, the terms of the Research and License Agreement and the First Amendment Agreement shall remain in full force and effect.

[Remainder of page intentionally left blank Signature page follows.]

  

  

  

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the date first written above.

	
Ramot at Tel Aviv Univ ty Ltd.

	
By: /s/ Ze’ev Weinfeld, Ph.D.

	
Name: Ze’ev Weinfeld, Ph.D.

	
Title: Executive Vice President, Business Development

	  
	
BiolineRx Ltd.

	
By: /s/ Yuri Shoshan

	
Name: Yuri Shoshan

	
Title: Vice President, Finance and Corporate Development

	  
	
Bar-Ilan Research and Development

	
By: /s/ Gabriel Kenan

	
Name: Gabriel Kenan

	
Title: C.E.O. Bar-Ilan Research & Development Company Ltd.

We, the undersigned, hereby confirm that we have read the Amendment Agreement, that its contents are acceptable to us and that we will act in accordance with its terms.

	
/s/ lrit Gil-Ad

	  
	
Dr.lrit Gil-Ad

	  
	  	  
	
/s/ Abraham Weizman

	  
	
Professor Abraham Weizman

	  
	  	  
	
/s/ Ada Rephaeli

	  
	
Dr. Ada Rephaeli

	  
	  	  
	
/s/ Abraham Nudelman

	  
	
Professor Abraham Nudelman

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]